---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-055286"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:43:44.869345+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verastem reports 52% ORR in PDAC and 42% ORR in NSCLC for KRAS G12D inhibitor VS-7375

## Summary
- Phase 1 data from China: 23 PDAC patients had 52% ORR and 100% DCR; 12 NSCLC patients had 42% ORR and 83% DCR.
- No dose-limiting toxicities observed across 100-900 mg QD; TRAEs mostly Grade 1/2; no TRAE-related deaths.
- U.S. Phase 1/2a study for VS-7375 to start at 400 mg dose; plans to evaluate monotherapy and combinations in pancreatic, colorectal, and NSCLC.
- Data presented at ASCO 2025; GenFleet is partner in China; Verastem holds rights in U.S. and other regions.

## SEC filing metadata
- accession: 0001104659-25-055286
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465925055286/0001104659-25-055286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465925055286/tm2516844d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-055286
- JSON: https://secwatch.observer/filing/0001104659-25-055286.json
- Plain text: https://secwatch.observer/filing/0001104659-25-055286.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.